Back to Search Start Over

Early toxicity of a phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07)

Authors :
Vaugier, Loig
Palpacuer, Clément
Rio, Emmanuel
Goineau, Aurore
Pasquier, David
Buthaud, Xavier
De Laroche, Guy
Beckendorf, Véronique
Sargos, Paul
Créhange, Gilles
Pommier, Pascal
Loos, Geneviève
Hasbini, Ali
Latorzeff, Igor
Silva, Marlon
Denis, Fabrice
Lagrange, Jean-Léon
Campion, Loïc
Supiot, Stephane
Bernardo, Elizabeth
Département de Radio-Oncologie [ICO, Nantes]
Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO)
UNICANCER-UNICANCER
Département de Biostatistiques [ICO, Nantes]
Service de la Radio-Oncologie [Angers]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille)
Université de Lille-UNICANCER
Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 (CRIStAL)
Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)
Département de Radio-Oncologie [Nantes] (Centre Catherine de Sienne)
Centre Catherine-de-Sienne [Nantes] (CCS)
Département de Radio-Oncologie [Saint-Priest en Jarez] ( Institut de Cancérologie de la Loire)
Institut de Cancérologie de la Loire [Saint-Priest en Jarez]
Département de Radio-Oncologie [Vandoeuvre-lès-Nancy] (Centre Alexis Vautrin)
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL)
Département de Radio-Oncologie [IB, Bordeaux] (Institut Bergonié)
Institut Bergonié [Bordeaux]
Service de radiothérapie [Centre Georges-François Leclerc]
Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL)
Département de Radio-Oncologie [CLB, Lyon] (Centre Léon Bérard)
Centre Léon Bérard [Lyon]
Département de Radio-Oncologie [Clermont-Ferrand] (Centre Jean Perrin)
Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP)
Département de Radio-Oncologie [Brest] (Clinique Pasteur)
Clinique Pasteur [Brest]
Département de Radio-Oncologie [Toulouse] (Oncorad Clinique Pasteur)
Oncorad Clinique Pasteur [Toulouse]
Département de Radio-Oncologie [Baclesse, Caen]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC)
Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
Centre Jean Bernard [Institut Inter-régional de Cancérologie - Le Mans]
Département de Radio-Oncologie [AP-HP Hôpital Henri Mondor]
Hôpital Henri Mondor
Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11)
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA)
Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14)
This study was funded by Astellas.
Université Lille Nord de France (COMUE)-UNICANCER
Centre Alexis Vautrin [Vandoeuvre-lès-Nancy]
Département de Radio-Oncologie [Dijon] (CGFL Dijon)
UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Source :
International Journal of Radiation Oncology, Biology, Physics, International Journal of Radiation Oncology, Biology, Physics, 2018, 103 (5), pp.1061-1067. ⟨10.1016/j.ijrobp.2018.12.020⟩, International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2018, 103 (5), pp.1061-1067. ⟨10.1016/j.ijrobp.2018.12.020⟩
Publication Year :
2018
Publisher :
HAL CCSD, 2018.

Abstract

International audience; PURPOSE:Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiotherapy as considered in the BLINDED trial, is an attractive option but with concerns about its toxicity. This article describes early toxicity with the technique.METHODS AND MATERIALS:BLINDED was a prospective multi-center phase II trial investigating high-dose salvage pelvic irradiation with an additional dose to the fluorocholine-based positron-emission-tomography (FCH-PET)-positive pelvic lymph nodes (PLN), combined with six-month androgen blockade. The prescribed dose was 54 Gy in 1.8 Gy fractions with up to 66 Gy in 2.2 Gy fractions to the pathological PLN. Early toxicity was defined until one year after radiotherapy. Patients quality of life was assessed using the EORTC questionnaires (QLQ-C30 and QLQ-PR25).RESULTS:Seventy-four patients were recruited in fifteen French radiation oncology departments between August 2014 and July 2016. Seven were excluded before treatment because of violation of the inclusion criteria. The intention-to-treat analysis therefore included sixty-seven patients. Half of them had received prior prostatic irradiation. Median age was 67.7 ± 6.5 years. Grade 2 acute urinary toxicity was observed in 9/67 patients (13.4%) and grade 2 one-year toxicity in 4/67 patients (6%). Three patients (4.4%) had grade 3 urinary toxicity. Grade 2 acute digestive toxicity was observed in 10/67 patients (14.9%) and grade 2 one-year toxicity in 4/67 patients (6%). Patients with prior prostate bed irradiation did not exhibit increased urinary or digestive toxicity. EORTC questionnaire scores at one year did not worsen significantly.CONCLUSIONS:The acute and one-year toxicity of the BLINDED protocol was satisfactory, even in patients with a past history of prostatic irradiation.

Details

Language :
English
ISSN :
03603016 and 1879355X
Database :
OpenAIRE
Journal :
International Journal of Radiation Oncology, Biology, Physics, International Journal of Radiation Oncology, Biology, Physics, 2018, 103 (5), pp.1061-1067. ⟨10.1016/j.ijrobp.2018.12.020⟩, International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2018, 103 (5), pp.1061-1067. ⟨10.1016/j.ijrobp.2018.12.020⟩
Accession number :
edsair.dedup.wf.001..73346dff18a5ee6066935aa243ca6f12
Full Text :
https://doi.org/10.1016/j.ijrobp.2018.12.020